Deals review
- Deals review
- Deal details
Agendia acquires rights to the discovery of a major drug resistance mechanism in breast cancer potentially leading to a Herceptin® sensitivity test
In order to access this content you must be logged in and have a subscription to Pharmalicensing Intelligence.
Pharmalicensing Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.
Related deals
Agendia announces a distribution agreement with Medvet Science, Australia.
Vysis and Genentech collaborate on cancer technologies
Power3 Secures Exclusive Rights to Its Early Detection Breast Cancer Test
DIAGNOCURE ACQUIRES RIGHTS FROM MCGILL UNIVERSITY TO POTENTIAL MARKERS FOR BREAST CANCER DETECTION
DIAGNOCURE ACQUIRES NEW HIGH VALUE DIAGNOSTIC TESTS FOR BREAST AND COLON CANCER
Health Discovery Corporation Licenses New Prostate Cancer Test to Abbott
Cytoclonal secures rights to bacterial drug resistance target
Celsion acquires Duke University's breast cancer hyperthermia treatment technology
Related categories
- Therapeutic target
- Oncology
- Breast cancer
- Industry sector
- Biotechnology
- Diagnostic
More deals
Latest deals
- Biovator and BASF sign technology development agreement
- Agfa HealthCare signs four-year agreement with Chinese partners for distribution of radiography solutions, potentially worth 500 million US dollar
- Omnicare Announces Acquisition of Continuing Care Rx
- Nabi Biopharmaceuticals Announces Long-Term Manufacturing Agreement With Diosynth RTP
- GreenVax Selects Xcellerex XDR Single-Use Bioreactors for New Vaccine and Biotherapeutics Program
Most viewed deals
- Recommended acquisition of Acambis plc ("Acambis") by Sanofi Pasteur Holding ("Sanofi Pasteur") by way of scheme of arrangement Posting of Scheme Document
- Omnicare Announces Acquisition of Continuing Care Rx
- Bayer CropScience and Janssen PMP conclude research agreement:
- Nabi Biopharmaceuticals Announces Long-Term Manufacturing Agreement With Diosynth RTP
- Biovator and BASF sign technology development agreement
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us